Ascendis Pharma A/S (NASDAQ:ASND) Stock Rating Reaffirmed by Cantor Fitzgerald

Ascendis Pharma A/S (NASDAQ:ASNDGet Rating)‘s stock had its “overweight” rating reaffirmed by investment analysts at Cantor Fitzgerald in a research report issued to clients and investors on Wednesday, PriceTargets.com reports. Cantor Fitzgerald also issued estimates for Ascendis Pharma A/S’s FY2022 earnings at ($9.07) EPS and FY2023 earnings at ($10.94) EPS.

A number of other analysts have also recently issued reports on ASND. Morgan Stanley lowered their target price on Ascendis Pharma A/S from $152.00 to $148.00 and set an “overweight” rating for the company in a research note on Thursday, August 11th. Wells Fargo & Company increased their target price on Ascendis Pharma A/S from $167.00 to $172.00 and gave the stock an “overweight” rating in a research note on Thursday. SVB Leerink lowered their target price on Ascendis Pharma A/S from $174.00 to $168.00 and set an “outperform” rating for the company in a research note on Thursday, August 11th. Oppenheimer lowered their target price on Ascendis Pharma A/S from $154.00 to $144.00 and set an “outperform” rating for the company in a research note on Thursday, August 11th. Finally, Berenberg Bank reissued a “buy” rating and set a $166.00 target price on shares of Ascendis Pharma A/S in a research note on Tuesday, August 30th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat, Ascendis Pharma A/S currently has an average rating of “Moderate Buy” and a consensus price target of $153.70.

Ascendis Pharma A/S Stock Performance

Ascendis Pharma A/S stock opened at $103.88 on Wednesday. The company has a current ratio of 9.66, a quick ratio of 8.78 and a debt-to-equity ratio of 0.82. Ascendis Pharma A/S has a 1 year low of $61.58 and a 1 year high of $172.65. The company has a market cap of $5.92 billion, a PE ratio of -13.17 and a beta of 0.66. The company’s 50-day moving average is $94.55 and its two-hundred day moving average is $96.67.

Ascendis Pharma A/S (NASDAQ:ASNDGet Rating) last released its earnings results on Wednesday, August 10th. The biotechnology company reported ($1.54) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.11) by $0.57. The company had revenue of $6.51 million for the quarter, compared to the consensus estimate of $7.07 million. Ascendis Pharma A/S had a negative net margin of 2,099.51% and a negative return on equity of 48.92%. Equities analysts anticipate that Ascendis Pharma A/S will post -8.69 earnings per share for the current year.

Institutional Investors Weigh In On Ascendis Pharma A/S

Several large investors have recently made changes to their positions in ASND. Goldman Sachs Group Inc. boosted its holdings in shares of Ascendis Pharma A/S by 3,024.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,754,458 shares of the biotechnology company’s stock valued at $205,903,000 after buying an additional 1,698,302 shares during the last quarter. Wellington Management Group LLP lifted its holdings in Ascendis Pharma A/S by 14.6% during the 1st quarter. Wellington Management Group LLP now owns 4,665,579 shares of the biotechnology company’s stock valued at $547,552,000 after purchasing an additional 594,855 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in Ascendis Pharma A/S by 6.1% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 5,165,375 shares of the biotechnology company’s stock valued at $480,173,000 after purchasing an additional 295,224 shares during the last quarter. Assenagon Asset Management S.A. acquired a new stake in Ascendis Pharma A/S during the 2nd quarter valued at $25,689,000. Finally, Capital International Investors acquired a new stake in Ascendis Pharma A/S during the 1st quarter valued at $28,894,000.

Ascendis Pharma A/S Company Profile

(Get Rating)

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia.

See Also

Analyst Recommendations for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.